Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Onconova Therapeutics, Inc.
Traws Pharma Announces New Employee Inducement Grants
April 02, 2024
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
April 02, 2024
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
March 08, 2024
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
December 12, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 28, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 14, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
November 07, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
November 02, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Expands Leadership Team with Two Key Appointments
October 24, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
October 19, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Encouraging Rigosertib Data Presented at EADV as Late Breaker
October 12, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
September 28, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
August 10, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
August 03, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
June 14, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
June 05, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
May 25, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 15, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
May 12, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
May 11, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
May 08, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
May 04, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
April 19, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
April 06, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
March 23, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
March 16, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
March 15, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
March 09, 2023
From
Onconova Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ONTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.